The Globe and Mail reports in its Thursday edition that Organigram Global says the acquisition of a European medical cannabis company has helped drive it to record quarterly revenues and fundamentally reshaped the firm. A Canadian Press dispatch to The Globe says the April purchase of German-based Sanity Group GmbH added $38-million in net revenue during the three-month period that ended on June 30. Organigram was already an investor in the company and acquired all its remaining issued and outstanding shares for 107 million euros(about $173.7-million). Founded in New Brunswick in 2013, Organigram's corporate offices are in Toronto with its flagship flower and ready-to-consume products facility located in Moncton. It produces hash and craft flower in LacSuprieur, Que.; edibles, including extracts, in Winnipeg; hydrocarbons and carbon dioxide for extracts and concentrates in Aylmer, Ont.; and handles distribution from London, Ont. Organigram said Sanity has about 10 per cent of the German cannabis market. Under its European growth strategy, the subsidiary is expanding operations in Switzerland, Britain, Poland and Czechia. Organigram claims an 11.1-per-cent share of the Canadian recreational cannabis market.